New method for the treatment of type 2 diabetes

     Oral insulin, interleukin-1β-cell receptor antagonists, anti-inflammatory drugs and SGLT2 inhibitors of type 2 diabetes treatment fliers about the field of new methods.

     Endocrine Metabolic Center, University of California, San Diego, Professor, Dr. Robert R. Henry pointed out that there are unusual for type 2 diabetes unknown pathway or known defects in the new method of treatment. As a San Diego health care system, endocrine metabolic branch of the President, he presided over the June 8 called "new treatment for type 2 diabetes," a symposium. There were four speakers for the 3 clinical trial has entered a new treatment methods and an NIH research project was carried out in the lectures.

     First of all, the Danish Steno Diabetes Center, Dr. Thomas Mandrup-Poulsen, "interleukin-1β receptor antagonist" as its theme interleukin-1β in abnormal insulin secretion and β-cell apoptosis in an early role was discussed.

     Dr. Henry commented: the initial study was to assess the blockade in patients with type 2 diabetes interleukin-1β receptor, could improve β-cell function, reducing the early β-cell apoptosis. In addition, this receptor antagonists, including endothelial and vascular function, and other organizations, including the role with an additional systematic. As a new anti-inflammatory way, the mechanism of type 2 diabetes as well as inflammation characterized by abnormal pathways in many other diseases with potentially far-reaching implications, is one of the hot current research.

     At the same time, interleukin -2 receptor antagonists are also being studied for the treatment of rheumatoid arthritis, gout, and adolescent idiopathic arthritis.

     Next, Kinexum LLC Chairman and CEO, Dr. Alexander Fleming reported on the "oral insulin - the theory and the current treatment methods."

     For many years, has been designed through the absorption of oral insulin buccal mucosa is always the research focus. Dr. Fleming introduced a special oral insulin absorption kinetics as well as their characteristics of high blood glucose.

     As a third speaker, Liverpool University Hospital, Dr. John P Wilding on "SGLT-2 inhibitors, the clinical effect" as to report on.

     Dr. Henry commented: sodium - glucose cotransporter protein (SGLT) -2 inhibitors by blocking the receptor in renal proximal tubule reabsorption of glucose inhibition. In the normal population and type 2 diabetes, SGLT-2 and 90% of the glucose re-absorption-related. When its activity was inhibited 30% -50%, it will lead to increased secretion of urine, concentration and urine volume increased, fasting blood glucose levels in patients with lower blood sugar levels eventually lead to the improvement and weight loss.

     After 12 weeks of study, SGLT-2 so that fasting glucose levels fell by an average 30-50mg/dL, glycated hemoglobin level of reduction of 0.5% -0.8%, subjects were weight loss of about 3-5 pounds (depending on the degree of obesity in patients).

     Although the SGLT-2 inhibitor, has been in existence for nearly 20 years, but in comparison with previous similar drugs, the new agents have a high specificity, unlike the role of traditional medicine as a wide range.

     Finally, the Boston Joslin Diabetes Center Clinical Research Department Director, an associate professor of medicine at Harvard Medical School, Dr. Allison B. Goldfine targeted by the Diabetes and Digestive and Kidney Diseases funded by the National Research Center, salicylate anti-inflammatory treatment of type 2 diabetes mellitus (TINSAL T2D research) was entitled "The anti-inflammatory drugs" lecture.

     As an anti-inflammatory drugs, salicylic acid ester type 2 diabetes mellitus a major role in the inflammation pathway in patients with overactive. Its diabetes glucose metabolism and blood vessel abnormalities have a positive effect. There is sufficient evidence to show that tissue and blood vessels involved in insulin resistance and inflammation, and may be related to abnormal insulin secretion.

     Dr. Henry concluded: four speakers on the new method for the treatment of diabetes, respectively, the area was wonderful speech, these treatments to improve the quality of life of diabetic patients has provided new hope. Although the study is still a long road, but that some large amounts of data support the potential value of further research.